Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neuraxpharm Buccolam Acquisition Opens Up Opportunities

Strikes Deal With Takeda For The Only Buccal Midazolam Approved Across Europe

Executive Summary

Neuraxpharm says a deal with Takeda to acquire the only buccal midazolam approved across Europe, Buccolam, not only gives the CNS specialist a strong asset but also offers the opportunity to expand its commercial footprint into the Nordics and Ireland.

You may also be interested in...



Neuraxpharm Expands In Switzerland With New Local Head

Neuraxpharm has appointed Jörg Gärtner to lead its business in Switzerland, as the CNS specialist prepares to roll out its medical cannabis portfolio in the region.

Neuraxpharm’s Brain Acquisition Stems From Expansion Ambitions

Privately-owned Neuraxpharm has found another company to give it further access to a new European market, picking up Athens-based Brain Therapeutics. It aims now to introduce its Buccolam (midazolam) in Greece.

Neuraxpharm Expands Into The Nordics With New Leader From Viatris

In line with its plan to expand into the Nordics, CNS specialist Neuraxpharm has established a new business unit in Stockholm and has recruited Viatris’ Magnus Wassén to lead it as general manager. The company is expecting Neuraxpharm Sweden to provide an immediate sales platform for Buccolam. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150247

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel